Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of chronic myeloid leukemia when imatinib fails.

Expert opinion on pharmacotherapy - 1 Feb 2011

Hehlmann Rüdiger, Jung-Munkwitz Susanne, Saussele Susanne

Abstract excerpt

INTRODUCTION: Imatinib failure represents a major clinical challenge in the management of chronic myeloid leukemia. AREAS COVERED: Definition of failure, its causes, the various approaches to the treatment of imatinib failure such as imatinib dose escalation, second-generation tyrosine kinase inhibitors and stem cell transplantation, and monitoring of residual disease are covered in this review. Selected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Genes, abl
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Molecular Diagnostic Techniques

Share to Piperazines

Share to Pyrimidines

Share to Treatment Failure

Source

Identifiers

PMID: 21226637
DOI: 10.1517/14656566.2011.533169

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of chronic myeloid leukemia when imatinib fails.PMID 21226637Read ↗

Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?Semantic proximity Read ↗

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?Semantic proximity Read ↗

Imatinib Mesylate — The New Gold Standard for Treatment of Chronic Myeloid LeukemiaSemantic proximity Read ↗

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.Semantic proximity Read ↗

State-of-the-art in the treatment of chronic myeloid leukaemia.Semantic proximity Read ↗

Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature ReviewSemantic proximity Read ↗

The development of imatinib as a therapeutic agent for chronic myeloid leukemiaSemantic proximity Read ↗

Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilitiesSemantic proximity Read ↗

Therapy options in imatinib failures.Semantic proximity Read ↗

Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and managementSemantic proximity Read ↗

Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications.Semantic proximity Read ↗

Clinical resistance to imatinib: mechanisms and implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.